Trastuzumab News and Research

RSS

Targeting PI3Kβ alone and with combination therapy in PTEN-deficient tumors

The cover for issue 11 of Oncotarget features Figure 6, "Effects of AZD8186 in combination with anti-PD1 on syngeneic models," by Owusu-Brackett, et al.

18 Mar 2020

NCCN publishes recommendations for assessing quality improvements in cancer care

The National Comprehensive Cancer Network has published a curated list of high-impact measures for assessing quality improvements in cancer care.

10 Mar 2020

New antibody-drug conjugate shows promising activity in salivary gland tumors

The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology.

7 Jan 2020

Obesity linked to increased risk of cardiotoxicity in chemotherapy-treated patients with breast cancer

Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such as trastuzumab. Both types of drugs are major culprits in chemotherapy-induced heart disease.

23 Dec 2019

Treatment combination improves survival in advanced HER2-positive breast cancer patients

Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.

11 Dec 2019

Cancer patients receiving common heart drugs have less heart damage from cancer therapy

Cancer patients receiving common heart drugs have less heart damage from cancer therapy, according to research presented today at EuroEcho 2019, a scientific congress of the European Society of Cardiology.

4 Dec 2019

Biosimilar for HER2+ breast cancer achieves similar overall response rate to reference drug

The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study reported at the ESMO Asia 2019 Congress.

22 Nov 2019

Promising method to identify aggressive breast cancers that will respond to immunotherapy

University of North Carolina Lineberger Comprehensive Cancer Center researchers have discovered a promising method to identify aggressive breast cancer tumors that will respond to drugs that unleash the immune system against cancer.

14 Nov 2019

Key metabolic changes found in patients with chemotherapy-related heart toxicity

More and more patients are being treated successfully for cancer. However, some cancer treatments that are very effective for breast cancer – medications like anthracyclines and trastuzumab – can cause heart dysfunction and lead to heart failure.

19 Jul 2019

New research shows significant gaps in deployment of 'coverage with evidence development'

Value in Health, the official journal of ISPOR- the professional society for health economics and outcomes research, announced today the publication of new research from The Netherlands showing important gaps in the deployment of "coverage with evidence development," a type of pharmaceutical managed entry agreement that gives patients access to treatments while additional evidence is being collected.

15 Jul 2019

Researchers develop DNA nanorobots that target breast cancer cells

According to the Mayo Clinic, about 20% of breast cancers make abnormally high levels of a protein called human epidermal growth factor receptor 2 (HER2).

17 Jun 2019

Medication could mitigate side effects of chemotherapy for breast cancer patients

Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a commonly used chemotherapy drug.

14 Mar 2019

CT scans used in cancer diagnostics can provide valuable clues to preventing heart problems

An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's risk for heart problems in the months and years after treatment.

7 Mar 2019

New identified biomarker predicts patients who might benefit from HER2-targeted agents

In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy.

22 Feb 2019

Study shows precision medicines could aid more breast cancer patients via RNA-targeting

When women or men receive the worrisome diagnosis of breast cancer, that news comes with an important piece of information, namely, whether their cancer is HER2-positive or HER2-negative.

8 Feb 2019

New substance could improve efficacy of established breast cancer treatments

Physicians from Karl Landsteiner University of Health Sciences in Krems (Austria) demonstrate potential for clinical application, collaborating with research groups from Germany, the USA, and China.

13 Dec 2018

Cancer patients who take beta-blocker along with breast cancer drug have less heart damage

Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented today at EuroEcho-Imaging 2018.

5 Dec 2018

Two genomic tests help identify most effective treatment for breast cancer patients

New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalized medicine ever nearer.

14 Nov 2018

New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers

An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumor activity in a number of cancers including those of the gullet (esophagus), stomach and bowel.